Compare SY & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | CABA |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.8M | 319.6M |
| IPO Year | 2018 | 2019 |
| Metric | SY | CABA |
|---|---|---|
| Price | $3.13 | $3.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.50 | ★ $14.57 |
| AVG Volume (30 Days) | 594.5K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $57.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $0.99 |
| 52 Week High | $6.28 | $3.78 |
| Indicator | SY | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 59.33 |
| Support Level | $2.80 | $2.11 |
| Resistance Level | $3.33 | $3.34 |
| Average True Range (ATR) | 0.15 | 0.28 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 62.28 | 53.54 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.